[Portfolio]

AdvanCell

AdvanCell is a clinical-stage radiopharmaceutical company leveraging 212Pb as a novel radioisotope, which we view as a potentially superior source of radiation that provides a more targeted hit on tumors with reduced exposure to healthy parts of the body. AdvanCell leverages a novel 212Pb production method that has potentially higher production capacity and lower COGS than competitors, and the company is also developing a pipeline of drug candidates that use 212Pb, led by a potentially best-in-class program in prostate cancer.

Back to portfolio